IDEC’s goal is to develop two major commercial franchises – one in oncology in certain B-cell non-Hodgkin’s lymphomas, the other in autoimmune and inflammatory diseases.
The success that IDEC experienced with Rituxan® (Rituximab) is being leveraged to other aspects of IDEC’s business. For example, our second investigational anti-cancer agent, Zevalin (Ibritumomab Tiuxetan), a radioimmunotherapy, builds on the foundations established developing and marketing Rituxan.
Currently, Rituxan has been approved for marketing in approximately 68 countries throughout the world.
On February 19, 2002, the Food and Drug Administration (FDA) approved Zevalin for marketing in the U.S. If approved in Europe, Zevalin will be marketed by Schering AG., the German company with exclusive marketing and distribution rights to Zevalin outside the U.S.
In the area of autoimmune and inflammatory diseases, IDEC’s broad expertise in product development leverages its capabilities in immunology, as well as its ability to develop, manufacture and market monoclonal antibodies.
IDEC products are directed at specific interactions between discrete cellular antigens which are believed to play critical roles in the pathogenesis of autoimmune and inflammation and allergy. Our product candidates are all monoclonal antibodies that target key pathways in the immune activation process, and offer a wide range of development opportunities.
Currently, IDEC has four product candidates in human clinical trials: three investigational agents in Phase II clinical trials – IDEC-151, IDEC-131 and IDEC-114. IDEC-152 is scheduled to enter a Phase I/II clinical trial in the first half of 2003.